/PRNewswire/ AlloSource®, one of the largest allograft providers in the U.S., creating innovative cellular and tissue allografts to help surgeons heal their.
TheraCell Announces Delivery Of Over 25,000 Of Its Licensed Bone Fiber Grafts
Products Have Reached an Annual End Customer Sales Rate Approaching $30M
News provided by
Share this article
Share this article
LOS ANGELES, Dec. 17, 2020 /PRNewswire/ TheraCell Inc., a leading allograft solution company, today announced that over 25,000 of its licensed demineralized bone fiber products have been delivered by its licensee partners. TheraCell s partners have seen steady double-digit quarter over quarter growth, now representing an annual end customer sales rate approaching $30M.
(PRNewsfoto/TheraCell, Inc.)
TheraCell has licensed the base fiber technology to AlloSource to produce and market AlloFuse® Cortical Fibers and AlloFuse® Fiber Boats, and to produce private label products to be marketed by other orthopedic companies. The technology has also been licensed to Australian Biotechnologies to produce and market AlloVance® Xpress Fibres, AlloVance® Xpress Hybrid, AlloVance®